title: Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience.
abstract: OBJECTIVE
  Compassionate-use oxaliplatin paclitaxel was assessed for toxicity and efficacy according to clinical platinum resistance status in cisplatin-carboplatin-pretreated advanced ovarian cancer patients.
  
  
  METHODS
  Thirty-seven patients, retrospectively grouped into four oxaliplatin-paclitaxel dose levels (mg/m2): (DL1: 100/135; DL2: 130-135/135; DL3: 100/160-175; DL4: 130-135/160-175), received oxaliplatin and paclitaxel every three to four weeks.
  
  
  RESULTS
  Thirty-one of thirty-seven treated patients were evaluable for activity, with 1 complete and 14 partial responses, (objective response rate: 48%, 95% CI: 31-66). Of 18 platinum-resistant patients 6 responded, and of 13 platinum-sensitive patients, 9 responded. One patient (3%) had two febrile neutropenia episodes, and eight (22%) and eleven patients (30%) had grades 3 and 4 neutropenia, respectively. Six patients (16%) experienced grade 3 peripheral neuropathy. The median response duration was 10.8 months, with a 23-month (range 8-54) median follow-up. Median progression-free and overall survivals were 9 months (95% CI: 7-12), and 25.2 months (95% CI: 12-39), respectively.
  
  
  CONCLUSIONS
  The antitumour activity of oxaliplatin-paclitaxel in platinum-resistant ovarian cancer patients accords with experimental data on the agents' lack of cross-resistance. Time-related progression parameters confirm it as a promising salvage treatment option.
authors.affiliation: Service d'Oncologie Médicale, Hôpital Saint-Louis, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Faivre
authors.forename: S
authors.initials: S
authors.lastname: Kalla
authors.forename: E
authors.initials: E
authors.lastname: Cvitkovic
authors.forename: O
authors.initials: O
authors.lastname: Bourdon
authors.forename: D
authors.initials: D
authors.lastname: Hauteville
authors.forename: L M
authors.initials: LM
authors.lastname: Dourte
authors.forename: M A
authors.initials: MA
authors.lastname: Bensmaïne
authors.forename: M
authors.initials: M
authors.lastname: Itzhaki
authors.forename: M
authors.initials: M
authors.lastname: Marty
authors.forename: J M
authors.initials: JM
authors.lastname: Extra
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D016879:Salvage Therapy
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D017239:Paclitaxel